Physician profile
David Sean Teaster
NPI 1699860692
$2,278.20
in general payments reported to CMS, 2019-2025
18 companies · $345 in 2025
The $345 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $261 · 2021: $297 · 2022: $437 · 2023: $372 · 2024: $352 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $584.31 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $365.33 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $314.86 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $308.25 | 2019-2023 | Dyanavel Xr |
| Sanofi Pasteur INC. | $171.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.98 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $77.62 | 2021-2022 | |
| Neos Therapeutics, LP | $66.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.35 | 2019-2025 | Gardasil 9, Pedvaxhib, Vaxneuvance |
| Pharming Healthcare, INC. | $46.70 | 2025 | Ruconest |
| Pfizer INC. | $44.73 | 2023-2025 | |
| Kaleo, INC. | $42.84 | 2020-2022 | |
| Lnhc, INC | $21.74 | 2025 | Zelsuvmi |
| Collegium Pharmaceutical, INC. | $18.96 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $16.92 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.21 | 2019 | |
| Abbott Laboratories | $14.78 | 2024 | Cell-Dyn |
| Hologic Sales and Service, LLC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Teaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.